GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
Brazil: 10 years of a Compulsory License on HIV drug Efavirenz
Symposium in Curitiba highlights the need for a collective fight to make medicines affordable. When governments are unreceptive, it is...
Victory: Gilead forced to withdraw Truvada® patent application in Argentina
Gilead prevented from obtaining an illegitimate monopoly at the expense of people’s health Activists in Argentina, including our partner...
Argentina: GEP filed new opposition to patent request for Hepatitis C drug
A significant step in ensuring access to treatment for the 800,000 people living with hepatitis C in Argentina. Earlier this...
Brazilian National Institute of Industrial Property Rejects Truvada® Patent Application
On 24 January 2017, Brazil’s National Institute of Industrial Property (INPI) made public a decision to reject the patent application...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify]